EcoR1 Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

EcoR1 Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-300,000	Closed	-$8.46M	–	60
2023 Q2	$8.46M	Buy	+300,000	New	+$7.2M	0.21%	37
2022 Q2	–	Sell	-115,236	Closed	-$5.32M	–	96
2022 Q1	$5.32M	Buy	+115,236	New	+$6.22M	0.17%	50
2021 Q3	–	Sell	-200,000	Closed	-$10.6M	–	76
2021 Q2	$10.6M	Buy	+200,000	New	+$10.7M	0.4%	32

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

EcoR1 Capital's ZNTL Position: Q3 2023 in Review

EcoR1 Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2023, closing a stake of 300,000 shares — an estimated $8.46M sold.

EcoR1 Capital first reported a position in ZNTL in Q2 2021 and held it in 3 quarters. The position peaked at $10.6M in Q2 2021. 137 funds tracked by Wall St. Rank hold ZNTL as of Q3 2023.

EcoR1 Capital reported no remaining Zentalis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
EcoR1 Capital sold 300,000 Zentalis Pharmaceuticals shares in Q3 2023, an estimated $8.46M.
EcoR1 Capital first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 3 quarters.
EcoR1 Capital's Zentalis Pharmaceuticals position peaked at $10.6M in Q2 2021.
137 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2023.

Based on EcoR1 Capital's 13F filing for Q3 2023, filed 14 Nov 2023.